The Legal 500: Pharmaceutical Advertising Country Comparative Guide

Published

Dec 03 2020

Written By

I'm a partner in our international Commercial group, based in Paris, where I provide our clients with strategic commercial advice.

Christian Lindenthal, LL.M.

Partner
Germany

As a partner in our Munich team, I advise clients in the life sciences and healthcare sectors on matters at the intersection of IP, unfair competition, and regulatory law. I am a member of our Intellectual Property Practice Group as well as our Life Sciences and Healthcare Sector Group.

Sally Shorthose

Partner
UK

As one of our firm's most experienced intellectual property partners, specialising in transactional IP matters, I offer a wealth of knowledge to businesses at the cutting edge of research, development and technology, in a variety of sectors for which IP is of prime importance.

Practices

Regulatory, Compliance & Administrative

Sectors

Life Sciences and Healthcare

Regions

Countries

Australia

The Legal 500: Pharmaceutical Advertising Guide 2021 is a practical cross-border insight into pharmaceutical advertising, with contributing editor Sally Shorthose.

Each chapter of this guide provides information about the current issues affecting pharmaceutical advertising in a particular country and addresses topics such as self-regulation, press releases, gifts, samples, grants or donations, anti-bribery rules, regulatory authorities and courts, as well as insight and opinion on the most common issues in their respective country.

Read our overview of Pharmaceutical Advertising laws and regulations applicable in:

Australia

Read our chapter here >

France

Read our chapter here >

Germany

Read our chapter here >

Read our chapter here >